IRCT20231210060317N1
Recruiting
Phase 3
Melatonin Administration as an Adjuvant Therapy in Preterm Infants with Neonatal Jaundice
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Enrollment
- 60
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Gestational age 32\-37 weeks
- •Serum bilirubin level below exchange transfusion threshold
- •Indirect hyperbilirubinemia
- •Postnatal age under 30 days
Exclusion Criteria
- •Underlying diseases and congenital anomalies in the neonate
- •Any signs of neonatal sepsis or other infections
- •Signs and risk factors of hemolysis
- •Acute or chronic respiratory diseases
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Melatonin Supplementation as adjuvant Therapy for Prevention of Bronchopulmonary Dysplasia in Neonatesbronchopulmonary dysplasiaTCTR20191211004Tanta University Hospital100
Active, not recruiting
Phase 1
Melatonin supplementation as an adjuvant therapy in neonatal respiratory distress syndromerespiratory distress syndromeneonatesrespiratorydistresssyndromeTCTR20200326001mohamed shawky elfarargy100
Recruiting
Phase 2
The effect of melatonin in the prevention of preeclampsiaIRCT20230930059563N1Kashan University of Medical Sciences60
Not yet recruiting
Not Applicable
Effectiveness of Melatonin in managing sleep impairment in Opioid withdrawal patientsCTRI/2022/05/042865Sri Guru Ram Rai Institute of Medical and Health Sciences
Active, not recruiting
Not Applicable
se of Melatonin in the control of pain in face fracturesAnxiety disorder, unspecifiedAtypical facial painF41.9G50.1RBR-878g2jniversidade de Pernambuco